Influence of CYP2C19*2 gene polymorphism on MACE after PCI
10.3969/j.issn.1008-0074.2014.05.08
- VernacularTitle:CYP2C19*2基因多态性对PCI术后MACE的影响
- Author:
Yunchai LIN
;
Hui CHEN
;
Xiaoying WU
- Publication Type:Journal Article
- Keywords:
Cytochrome P-450 enzyme system;
Angioplasty,transluminal,percutaneous coronary;
Blood stasis
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2014;23(5):501-505
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the impact of cytochrome P450 oxidase (CYP2C19) *2 genotype on major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) and impact of MACE on blood stasis indexes .Methods :From Jan 2010 to Jan 2011 ,a total of 355 patients with blood stasis syndrome undergoing PCI were enrolled .All patients took aspirin and clopidogrel conventionally before PCI ,then maintained for one year at least after PCI .According to MACE or not ,patients were divided into MACE group (n=64) and no MACE group (n=291) .Turbidimetry method was used to measure platelet aggregation rate before and one week after PCI ,and polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP ) was used to test CYP2C19 * 2 gene polymorphism .Results:(1) Compared with no MACE group ,there were significant rise in maximum platelet aggregation rate [MPA ,(36.38 ± 14.57)% vs .(44.87 ± 11.63)% ] and residue platelet aggregation rate [RPA , (25.76 ± 12.69)% vs .(34.45 ± 15.58)% ] , P< 0.01 both ;in percentage of CYP2C19*2 gene mutation (GA+AA) (36.43% vs .75.0% ,χ2 =27.832 ,P<0.01) in MACE group .(2) Multi-factor Logistic regression analysis in-dicated that >65 years ,CYP2C19*2 gene mutation (GA+AA) ,renal dysfunction (creatinine>1.5mg/dl) and re-duced left ventricular ejection fraction (LVEF< 50% ) were independent risk factors for MACE after PCI (OR=2.164~5.947 , P<0.05 or <0.01);(3) Binary linear correlation analysis indicated that CYP 2C19*2 gene muta-tion was positively correlated with RPA after PCI ( r=0.437 , P<0.001) .Conclusion:CYP2C19*2 gene mutation affects antiplatelet activity of clopidogrel ,so it′s helps to recognize MACE risk in patients with coronary heart dis-ease and blood stasis after PCI .
